Crossmark

Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: E-SPERANZA COVID Project study protocol

Crossref DOI link: https://doi.org/10.1186/s13063-021-05951-w

Published Online: 2022-01-06

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mera-Cordero, Francisco http://orcid.org/0000-0002-6599-0506
Bonet-Monne, Sara

Almeda-Ortega, Jesús

García-Sangenís, Ana

Cunillera-Puèrtolas, Oriol

Contreras-Martos, Sara

Alvarez-Muñoz, Gemma

Monfà, Ramon

Balanzo-Joué, Marina

Morros, Rosa

Salvador-Gonzalez, Betlem
Funding

Funding for this research was provided by:

Instituto de Salud Carlos III
License Information

Text and Data Mining valid from 2022-01-06

Version of Record valid from 2022-01-06
More Information

Article History

Received: 24 September 2021

Accepted: 17 December 2021

First Online: 6 January 2022

Change Date: 9 February 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1186/s13063-022-06073-7

Declarations

:

: The authors declare that they have no competing interests.

Updates are available Correction dated 2022-02-09

Click to view Correction: https://doi.org/10.1186/s13063-022-06073-7